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Abstract: Background and purpose: Given the great clinical heterogeneity of atrial fibrillation (AF)
patients, conventional classification only based on disease subtype or arrhythmia patterns may not
adequately characterize this population. We aimed to identify different groups of AF patients who
shared common clinical phenotypes using cluster analysis and evaluate the association between
identified clusters and clinical outcomes. Methods: We performed a hierarchical cluster analysis
in AF patients from AMADEUS and BOREALIS trials. The primary outcome was a composite of
stroke/thromboembolism (TE), cardiovascular (CV) death, myocardial infarction, and/or all-cause
death. Individual components of the primary outcome and major bleeding were also assessed.
Results: We included 3980 AF patients treated with the Vitamin-K Antagonist from the AMADEUS
and BOREALIS studies. The analysis identified four clusters in which patients varied significantly
among clinical characteristics. Cluster 1 was characterized by patients with low rates of CV risk
factors and comorbidities; Cluster 2 was characterized by patients with a high burden of CV risk
factors; Cluster 3 consisted of patients with a high burden of CV comorbidities; Cluster 4 was
characterized by the highest rates of non-CV comorbidities. After a mean follow-up of 365 (standard
deviation 187) days, Cluster 4 had the highest cumulative risk of outcomes. Compared with Cluster
1, Cluster 4 was independently associated with an increased risk for the composite outcome (hazard
ratio (HR) 2.43, 95% confidence interval (CI) 1.70–3.46), all-cause death (HR 2.35, 95% CI 1.58–3.49)
and major bleeding (HR 2.18, 95% CI 1.19–3.96). Conclusions: Cluster analysis identified four
different clinically relevant phenotypes of AF patients that had unique clinical characteristics and
different outcomes. Cluster analysis highlights the high degree of heterogeneity in patients with AF,
suggesting the need for a phenotype-driven approach to comorbidities, which could provide a more
holistic approach to management aimed to improve patients’ outcomes.
Keywords: atrial fibrillation; cluster analysis; phenotype classification; stroke
1. Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide and despite
substantial progress in its clinical management, it is still associated with high morbid-
ity and mortality [1]. Of note, in most cases, AF occurs with other comorbidities and
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cardiovascular (CV) risk factors which confer a great clinical variety to this condition,
implying the need for a holistic approach to the patients [2–9]. Given this heterogeneity,
conventional classification only based on disease subtype or arrhythmia patterns may
not adequately characterize the AF patient population. In recent years, several efforts
have been made to improve the taxonomy of clinical classification of AF and other con-
comitant CV conditions (e.g., heart failure, valvular aortic stenosis, pulmonary arterial
hypertension) by using different machine learning approaches [10–12]. One of the most
popular unsupervised algorithms is cluster analysis which has recently been shown to be
an excellent statistical approach for capturing relevant dissimilarities in disease phenotypes
and identifying different patients’ clusters with distinct outcomes [13–18]. Cluster analysis
is an exploratory statistical tool aimed at generating natural groups (or clusters) within
the data [19]. The analysis is able to identify patients who are phenotypically homogenous
and group them based only on measured different clinical characteristics between cases
without investigators’ supervision [19]. Accordingly, by using pooled individual patient
data from two randomized, open-label AF trials (AMADEUS and BOREALIS) [20,21], we
aimed to identify different groups of AF patients who shared common clinical phenotypes
applying cluster analysis and to evaluate the association between identified clusters and
trial-adjudicated clinical outcomes.
2. Materials and Methods
2.1. Study Design and Cohort
For the present study, we used a pooled individual patient data of AMADEUS and
BOREALIS randomized, open-label clinical trials [20,21]. The full details of the designs
and the results of the two trials have been previously reported [20,21] and summarized in
Appendix A. In brief, the AMADEUS trial [20] was a multicentre, randomized, open-label,
assessor blind, non-inferiority study comparing the efficacy and safety of once-weekly
subcutaneous idraparinux with adjusted-dose oral vitamin-k antagonists (VKA) in the
prevention of thromboembolic events (TE) in patients with AF. The trial was stopped early
because of excess clinically relevant bleedings in the idraparinux arm [20]. Comparably,
the BOREALIS trial [21] was a multicentre, randomized, double-blind, double-dummy,
non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous
idrabiotaparinux (or its placebo) with oral adjusted-dose warfarin in the prevention of
stroke and systemic TE in patients with AF. The study was stopped prematurely by the
sponsor for strategic/commercial, and not scientific, reasons [21]. Both trial protocols
were approved by the institutional review board and all patients have provided written
informed consent [20,21].
In our analysis, we included only AF patients treated with VKA. As required by
cluster analysis, patients with missing data for any variables were excluded.
2.2. Study Outcomes
In this pooled analysis, we included all outcomes collected from the initiation of
the treatment to the end of the studies. All outcomes were defined according to the
original trials and have been previously reported [20,21]. Suspected outcome events in
both trials were assessed by each independent central adjudication committee unaware
of the treatment assignment. For the purpose of this analysis, the primary outcome
was a composite of stroke/TE, CV death, myocardial infarction, and/or all-cause death.
Individual components of the composite outcome and major bleeding (i.e., fatal bleeding,
intracranial, or affected another critical anatomical site, or overt bleeding with a fall in the
haemoglobin level of ≥20 g/L or requiring transfusion of ≥2 units of red blood cells). For
the present analysis, we used only the first event of each outcome.
2.3. Statistical Analysis
We performed an agglomerative hierarchical cluster analysis for finding clusters
of patients based on pre-specified clinical variables. The analysis aimed to identify the
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optimal number of clusters that were homogenous and indicative of a clinically relevant
phenotypic subgroup of AF patients without prior knowledge of the outcomes. We used
Ward’s minimum variance method in order to minimize the total within-cluster variance
and we selected the squared Euclidean as a measure of distance or dissimilarity. The
squared Euclidean distance was used because we selected only dichotomous variables.
The following 12 baseline clinical variables were selected (all variables were considered as
binary): sex, age > 75, anaemia (i.e., haemoglobin levels <120 g/L in women and <130 g/L
in men), arterial hypertension, heart failure, diabetes mellitus, previous stroke/TE, coronary
artery disease (CAD), chronic kidney disease (CKD) (i.e., eGFR< 60 mL/min), type of AF
(permanent vs. paroxysmal/persistent), body mass index (BMI) classes (normal weight vs.
overweight or obese) and use of any antiplatelets.
The algorithm begins with each element (i.e., patient) as a separate cluster and then
proceeds with a “bottom-up” approach grouping each cluster with the most similar one
until all clusters became one. The hierarchical clustering process is visually represented
by a dendrogram graph in which vertical lines represent clusters that are joined together
and the position of the line on the scale indicates the distance at which clusters were
joined (the greater the difference in height, the more dissimilarity exists between clusters).
The ideal number of clusters was not prespecified and was identified by examining the
distances between cluster coefficients and further confirmed by visual inspection of the
dendrogram created. By using this approach, we found that the grouping became more
heterogeneous after being expanded to four clusters. Therefore, a 4-cluster model was
used for this analysis. Once clusters were identified, we assessed the association between
clusters and clinical characteristics and outcomes.
Continuous variables are reported as the median and interquartile range (IQR) or mean
and standard deviation (SD). Categorical variables are described as counts with percentages.
Among-clusters comparisons were conducted using the Kruskal-Wallis test for continuous
and ordinal variables and using the Chi-square test or Fisher’s exact test (if any expected cell
count was less than five) for categorical variables. Unadjusted and multivariate-adjusted
Cox proportional hazards models were used to estimate the association between clusters
and clinical outcomes. We built two multivariate models: for assessing all-cause death and
the composite outcome of stroke/TE, CV death, myocardial infarction, and/or all-cause
death, Model 1 was adjusted for CHA2DS2VASc score, and Model 2 was adjusted for age,
sex, and type of AF. To evaluate the association between clusters and major bleeding events,
Model 1 was adjusted for HASBLED score instead of the CHA2DS2VASc score whereas
Model 2 was adjusted for the same covariates as reported above (i.e., age, sex, and type
of AF). The hazard ratio (HR), the 95% confidence interval (CI), and the corresponding
p-value were reported. Kaplan-Meier curves of outcomes were assessed and comparisons
among different clusters were made using the Log-rank test. In all analyses, a two-tailed
p-value of <0.05 was considered statistically significant. Statistical analysis was performed
using SPSS® (version 26).
3. Results
Among the original 4169 AF patients treated with VKA from the merged dataset
of the AMADEUS and BOREALIS studies, 3980 patients had complete baseline data
for the 12 pre-specified clinical variables and were included in our study. The analysis
identified four patient clusters as shown in the dendrogram (Figure 1). Baseline clinical
characteristics according to the four clusters were compared and are reported in Table 1.
The key characteristics of each patient cluster are described below.
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sisted in the high burden of CV comorbidities and risk factors such as heart failure (77.7%), 
CAD (48.3%), hypertension (97.1%), and obesity (median BMI 30 (27–35)). Reflecting the 
high rate of CAD, the use of concomitant antiplatelet agents was higher compared to other 
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N = 1223 p Value
Age, years, median (IQR) 71 (64–76) 68 (61–73) 65 (59–70) 76 (70–79) <0.001
Age, years, mean (SD) 69.4 (9.4) 67.5 (8.0) 64.4 (7.9) 74.4 (8.0) <0.001
Females, n (%) 516 (33.7) 160 (40.3) 279 (33.6) 505 (41.3) <0.001
BMI, median (IQR) 27 (24–30) 31 (27–35) 30 (27–35) 28 (25–31) <0.001
BMI Classes, n (%) <0.001
Normal Weight 474 (31.0) 42 (10.6) 22 (2.7) 292 (23.9)
Overweight 636 (41.6) 123 (31.0) 324 (39.0) 527 (43.1)
Obese 420 (27.4) 232 (58.4) 484 (58.3) 404 (33.0)
Permanent AF, n (%) 779 (50.9) 242 (61.0) 521 (62.8) 664 (54.3) <0.001
CHA2DS2-VASc, median (IQR) 3 (2–4) 4 (3–5) 4 (3–5) 5 (4–6) <0.001
HAS-BLED, median (IQR) 2 (1–2) 2 (1–2) 2 (1–2) 2 (2–3) <0.001
Previous TE, n (%) 466 (30.5) 51 (12.8) 116 (14.0) 439 (35.9) <0.001
Hypertension, n (%) 1041 (68.0) 366 (92.2) 806 (97.1) 1144 (93.5) <0.001
Heart Failure, n (%) 273 (17.8) 59 (14.9) 645 (77.7) 572 (46.8) <0.001
Diabetes Mellitus, n (%) 62 (4.1) 387 (97.5) 275 (33.1) 307 (25.1) <0.001
CAD, n (%) 362 (23.7) 77 (19.4) 401 (48.3) 628 (51.3) <0.001
CKD, n (%) 61 (4.0) 37 (9.3) 24 (2.9) 435 (35.6) <0.001
Anaemia, n (%) 43 (2.8) 31 (7.8) 0 (0) 413 (33.8) <0.001
Any Antiplatelet Drugs, n (%) 121 (7.9) 5 (1.3) 442 (53.3) 404 (33.0) <0.001
TTR, median (IQR) 60 (46—71) 57 (43–73) 58 (40–73) 59 (43–73) 0.10
AF = atrial fibrillation; BMI = body mass index; CAD = coronary artery disease; CKD = chronic kidney disease; IQR = interquartile range;
N = number; TE = thromboembolic events; TTR = time in therapeutic range.
Biomedicines 2021, 9, 843 5 of 11
3.1. Clusters
3.1.1. Cluster 1 (n = 1530)
Cluster 1 was the largest cluster including 1530/3980 (38.4%) patients. Patients in this
cluster were characterized by low rates of CV risk factors and comorbidities as reflected by
the lowest CHA2DS2-VASc score compared to the other clusters (median 3, (2–4), p < 0.001).
Particularly, patients were least likely to have hypertension and diabetes mellitus (both
p < 0.001) and they had the lowest BMI (median 27 (24–30) kg/m2, p < 0.001).
3.1.2. Cluster 2 (n = 397)
This was the smallest cluster and was characterized by patients being more likely to be
male (60.7%) with a high burden of CV risk factors including the highest rates of diabetes
mellitus (97.5%) and obesity (58.4%) (both p < 0.001). Patients in this cluster had the lowest
rate of CAD (19.4%) and heart failure (14.9%) (both p < 0.001). Given the lowest rate of CAD,
patients were the least likely to be treated with concomitant antiplatelets (1.3%, p < 0.001).
3.1.3. Cluster 3 (n = 830)
Patients in this cluster were the youngest (median 65 (59–70) years) and the most likely
to be male (66.4%). The key and distinguishing characteristics of this cluster consisted in
the high burden of CV comorbidities and risk factors such as heart failure (77.7%), CAD
(48.3%), hypertension (97.1%), and obesity (median BMI 30 (27–35)). Reflecting the high
rate of CAD, the use of concomitant antiplatelet agents was higher compared to other
clusters (53.3%, p < 0.001). Concerning AF patterns, Cluster 3 patients had the highest rate
of permanent AF (62.8%, p < 0.001).
3.1.4. Cluster 4 (n = 1221)
Cluster 4 was the second largest cluster (1223/3980, 30.7%). It was characterized by
older patients (median 76, (70–79) years) who were more likely to be female compared to
the other clusters (41.3%, p < 0.001). Cluster 4 had the unique characteristic of the highest
rates of non-CV comorbidities, including anaemia (33.8%), CKD (35.6%), and previous TE
(35.9%) (all p < 0.001 compared to other clusters). Given the high burden of comorbidities,
patients in this Cluster had the highest CHA2DS2-VASc and HASBLED scores (median 5,
(4–6) and median 2 (2–3), respectively, p < 0.001).
3.2. Associations with Clinical Outcomes
Table 2 compares the crude rates of major adverse events among Clusters. Over a
mean follow-up of 365 (standard deviation (SD) 187) days, the occurrence of the composite
outcome and all-cause death, was higher in Cluster 4 (8.3% and 6.6%) compared to Cluster 1
(3.1% and 2.5%), Cluster 2 (5.0% and 3.5%), and Cluster 3 (3.7% and 3.3%, respectively) (all
p < 0.001). These findings were consistent also when considering individual components of
the composite outcome and major bleeding events (Table 2).








N = 1223 p Value
Composite outcome, n (%) 47 (3.1) 20 (5.0) 31 (3.7) 102 (8.3) <0.001
All-cause death, n (%) 38 (2.5) 14 (3.5) 27 (3.3) 81 (6.6) <0.001
Stroke/TE, n (%) 15 (1.0) 8 (2.0) 10 (1.2) 30 (2.5) 0.013
Cardiovascular death, n (%) 17 (1.1) 5 (1.3) 13 (1.6) 41 (3.4) <0.001
Myocardial infarction, n (%) 2 (0.1) 2 (0.5) 3 (0.4) 10 (0.8) 0.05
Major bleeding, n (%) 17 (1.1) 8 (2.0) 10 (1.2) 34 (2.8) 0.005
N, number; SE, systemic thromboembolism; composite outcome = stroke/TE, CV death, myocardial infarction, and/or all-cause death.
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As shown in Kaplan Meier curves patients in Cluster 4 had the highest cumulative
risk of outcomes (Figure 2A–C).
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Figure 2. Kaplan-Meier curves for the composite outcome of stroke/thromboembolism, cardiovascular death, myocardial
infarction and/or all cause-death (A), all-cause death (B), and major bleeding (C).
The unadjusted and multivariate-adjusted Cox proportional hazards analyses esti-
mating the association between clusters and clinical outcomes are reported in Table 3.
Cluster 1 was used as the comparator group since it was the Cluster with lower rates of
outcomes compared to other Clusters. In the unadjusted Cox analysis, when compared
with Cluster 1, Cluster 4 had a significantly higher risk for the composite outcome (HR 2.59,
95% CI 1.83–3.66), all-cause death (HR 2.47, 95% CI 1.68–3.63), and major bleeding (HR
2.42, 95% CI 1.35–4.34). After the adjustments according to multivariate models (Model 1
(M1)) adjusted for CHA2DS2-VASc score for the composite outcome and all-cause death
or HASBLED for major bleeding outcome, Model 2 (M2) adjusted for age, sex, and type
of AF) Cluster 4 was independently associated with an increased risk for the composite
outcome (M1: HR 1.86, 95% CI 1.26–2.73; M2: HR 2.43, 95% CI 1.70–3.46), all-cause death
(M1: HR 1.82, 95% CI 1.18–2.81; M2: HR 2.35, 95% CI 1.58–3.49), and major bleeding (M1:
HR 1.96, 95% CI 1.07–3.57; M2: HR 2.18, 95% CI 1.19–3.96), with no significant association
between Cluster 2 and Cluster 3 with the risk of all outcomes (Table 3).
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Table 3. Unadjusted and adjusted Cox regression analysis for all-cause death and the composite outcome.
Unadjusted Analysis Multivariate Analysis[Model 1]
Multivariate Analysis
[Model 2]
HR 95% CI p HR 95% CI p HR 95% CI p
Composite outcome *
Cluster 1 (ref) - - - - - - - - -
Cluster 2 1.62 0.96–2.73 0.07 1.48 0.88–2.50 0.14 1.63 0.96–2.75 0.07
Cluster 3 1.07 0.68–1.69 0.77 0.94 0.59–1.49 0.81 1.12 0.70–1.79 0.63
Cluster 4 2.59 1.83–3.66 <0.001 1.86 1.26–2.73 0.002 2.43 1.70–3.46 <0.001
All cause-death *
Cluster 1 (ref) - - - - - - - - -
Cluster 2 1.38 0.75–2.55 0.30 1.27 0.66–2.36 0.44 1.37 0.74–2.53 0.31
Cluster 3 1.12 0.68–1.85 0.64 1.01 0.61–1.66 0.98 1.16 0.69–1.92 0.58
Cluster 4 2.47 1.68–3.63 <0.001 1.82 1.18–2.81 0.006 2.35 1.58–3.49 <0.001
Major Bleeding §
Cluster 1 (ref) - - - - - - - - -
Cluster 2 1.76 0.76–4.09 0.18 1.89 0.81–4.39 0.13 1.90 0.81–4.44 0.13
Cluster 3 1.01 0.46–2.20 0.98 1.01 0.46–2.21 0.97 1.21 0.54–2.71 0.63
Cluster 4 2.42 1.35–4.34 0.003 1.96 1.07–3.57 0.02 2.18 1.19–3.96 0.01
CI = confidence interval; HR = hazard ratio; ref = reference. * Model 1: adjusted analysis for CHA2DS2VASc score; Model 2: adjusted
analysis for age, sex, and type of atrial fibrillation; § Model 1: adjusted analysis for HASBLED; Model 2: adjusted for age, sex, and type of
atrial fibrillation.
4. Discussion
To the best of our knowledge, the present study is one of the largest analyses of AF
patients based on this statistical approach for trial-adjudicated clinical outcomes. The
main findings of our study are as follows: (i) Cluster analysis was able to identify four
statistically-driven groups of AF patients which are clinically relevant and present distinct
phenotype characteristics; (ii) each patient Cluster was markedly different from the other
not only on the basis of measures which commonly drive conventional classifications
of AF (e.g., AF patterns) but each Cluster significantly varied among the measures of
demographic characteristics, CV-risk factors, comorbidities, and concomitant treatment;
(iii) importantly, the identified Clusters exhibited different risk for all-cause death and
major clinical adverse events.
Conventional classifications, only based on AF patterns (i.e., paroxysmal, persistent,
and permanent) might be limited by the natural progression of the disease and often
overlook the variety of underlying conditions that are commonly associated with AF [22].
In this study, we have applied a novel statistical approach to a large cohort of anticoagulated
AF patients derived from two multicentre randomized clinical trials. Our results underline
the great heterogeneity of AF highlighting the need for a disease classification of AF
patients that should encompass all possible clinical phenotypes.
This cluster analysis reinforces the importance of identifying possible patient pheno-
types which share clinical characteristics and common risk factors. Despite cluster analysis
might be not easily applied in daily clinical practice, the information provided by our study
further strengthen the concept that AF patients need improved clinical characterization
beyond the mere classification by the arrhythmia patterns
Our analysis found four main clinical phenotypes. The first cluster was characterized
by low rates of CV risk factors and comorbidities, such as hypertension, diabetes mellitus,
and the lowest rate of permanent AF. Not surprisingly, this cluster had the lowest rates of
adverse outcomes including all-cause death, CV death, and major bleeding. Cluster 2 and
Cluster 3, were characterized by a high burden of CV risk factors and CV comorbidities, as
reflected by a higher CHA2DS2-VASc score. Despite these two clusters seeming similar,
the key distinguishing characteristics of Cluster 3 compared to Cluster 2 is the higher
prevalence of cardiac comorbidities, such as heart failure or CAD which are significantly
lower in the latter. Finally, Cluster 4 is characterized by older patients with the unique
characteristic of the highest rates of non-CV comorbidities including anaemia, CKD, and
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previous TE thus conferring a higher risk of adverse outcomes during the follow-up despite
oral anticoagulation.
Cluster analysis has been recently applied in other observational AF cohorts. Indeed,
if we review the available data in the literature, some important comparisons can be made
between our study and previous analyses based on this statistical approach. One of the
first studies that applied cluster analysis in a large cohort of AF patients was conducted
by Inohara et al. [10]. Using data from the ORBIT-AF Registry, the study showed that
unsupervised cluster analysis was able to identify four clinically relevant AF phenotypes
(i.e., low comorbidity cluster, young/behavioural disorder cluster, device implantation
cluster, atherosclerotic-comorbid cluster) [10]. Similar to our analysis, when compared to
the low comorbidity cluster, the occurrence of major adverse CV events was significantly
higher in the three other clusters, even after the adjustment with CHA2DS2VASc score
(younger/behavioural disorder cluster: HR, 1.49; 95% CI, 1.10–2.00; device implantation
cluster: HR, 1.39; 95% CI, 1.15–1.68; and the atherosclerotic comorbid cluster: HR, 1.59; 95%
CI, 1.31–1.92) [10]. More recently, a cluster analysis based on Japanese AF patients from
the cohort of the Keio Interhospital Cardiovascular Studies for AF (KiCS-AF) registry [11]
similarly detected an atherosclerotic comorbid AF cluster phenotype, as was found in
the US cohort from the ORBIT-AF registry [10,11]. However, conventional classifications,
such as type of AF or LA size, did not drive cluster formation in the US cohort [10] while
contributing to the formation of clusters in the KiCS-AF registry [11]. Moreover, in the
analysis from the ORBIT-AF registry [10], one of the clusters identified was characterized
by younger age, high rates of liver disease, alcohol or drug abuse, and current smoking
(namely, the younger//behavioural cluster). Interestingly, these key variables that signif-
icantly contributed to the cluster formation in the ORBIT-AF cohort, were lower, if not
completely absent, in the Japanese cohort [10,11].
These findings further emphasize that determinants of AF may greatly vary across
different regions and enrich the debate on the great heterogeneity existing among AF
patients worldwide [23]. Hence, the move towards a more holistic and integrated approach
to AF management, as promoted in recent AF guidelines [24–26]. With the introduction of
the ABC (Atrial fibrillation Better Care) pathway, i.e., ’A’ Anticoagulation/Avoid stroke;
‘B’ Better symptom management; ‘C’ Cardiovascular and Comorbidity optimization [24],
identifying clinically relevant phenotype groups of AF patients could be useful for a more
tailored clinical approach. From the perspective of such an integrated approach, cluster
analysis may be a good ally to further understand the complex nature of AF patients, facili-
tate management decision-making, and improve their outcomes. For example, patients in
Cluster 2 had a high burden of CV risk factors but low rates, or not as of yet phenotypi-
cally expressed, CV comorbidities such as CAD or heart failure. Thus, for these patients,
lifestyle modifications and strict control of CV factors could be representing the most
effective treatments which should be promptly undertaken to prevent adverse outcomes.
In contrast, Cluster 4, which is characterized by a higher burden of non-CV comorbidities,
showed a significantly higher risk for all-cause death and CV events despite the use of oral
anticoagulation, highlighting that oral anticoagulation alone without an optimal treatment
of comorbidities, is insufficient to improve clinical outcomes.
In line with this concept, especially in high-risk patients, cluster analysis re-emphasizes
the importance of more comprehensive management of AF patients which should encom-
pass all three steps of the ABC pathway [27–29].
Cluster analysis is not to be considered as a formal proposal of a new classification
system for AF. Our aim was to apply a novel validated statistical approach to a large cohort
of AF patients that can capture relevant clinical factors and phenotypic similarities often
overlooked in conventional classifications. Our study, therefore, suggests that along with
conventional classifications, new strategies that are able to be clinically relevant in defining
phenotype groups could be a step toward precision medicine and a more comprehensive
characterisation of AF patients.
Biomedicines 2021, 9, 843 9 of 11
Limitations
Some limitations of our study should be acknowledged. First, identified clusters may
vary according to patient characteristics and available data. We arbitrarily selected the most
common comorbidities and risk factors that characterize AF patients. We are conscious that
the incorporation of more clinical characteristics, such as cognitive impairment that has
been demonstrated to have a relevant impact on AF patient outcomes [8,9,30], might yield
different results. However, since cluster analysis necessitates complete data on individual
patients, we chose to select a relatively small number of well-documented variables in
order to include as many patients as possible.
Second, the optimal number of clusters may be difficult to determine since different
statistical algorithms may generate different results and the final selection of four clusters
was based in part on investigator discretion. Despite the strength of this analysis as
the adjudicated clinical outcomes from the posthoc analysis of the two trial cohorts, the
multivariate Cox regression analysis may be limited due to the relatively small number
of events. As this study is a post hoc ancillary analysis of two controlled clinical trials
in which patients were treated only with VKA, the population might not fully reflect a
contemporary real-world AF population. Treatment strategies and clinical practice have
changed over time, partly limiting the generalization of the results. Nevertheless, we
considered a large cohort of AF patients with a high level of data quality and with centrally
adjudicated clinical outcomes. For these reasons, our analysis should be considered to be
hypothesis-generating and further studies are warranted to confirm our findings and the
strength of this statistical approach.
5. Conclusions
Among a large cohort of AF patients from the AMADEUS and BOREALIS trials,
cluster analysis identified four different clinically relevant phenotypes that had unique
clinical characteristics and different outcomes. Cluster analysis highlights the high degree
of heterogeneity in patients with AF suggesting the need for a phenotype-driven approach
to comorbidities which could provide a more holistic approach to management aimed to
improve patients’ outcomes.
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Appendix A. Supplemental Methods
The AMADEUS trial (20) was a multicentre, randomized, open-label non-inferiority
study with blinded assessment of outcome that compared fixed-dose idraparinux with
conventional anticoagulation by dose-adjusted oral vitamin K antagonist (VKA) therapy
for the prevention of thromboembolism in atrial fibrillation (AF) patients. Inclusion crite-
ria: ECG-documented non-valvular AF and an indication for long-term anticoagulation,
based on the presence of at least 1 of the following risk factors: previous ischemic stroke,
transient ischemic attack or systemic embolism, hypertension requiring drug treatment,
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left ventricular dysfunction (left ventricular ejection fraction <45% or symptomatic con-
gestive heart failure), age > 75 years, or age 65 to 75 years with either diabetes mellitus or
symptomatic coronary artery disease (previous myocardial infarction or angina pectoris).
Exclusion criteria included: indication for VKA other than AF, active bleeding or high risk
of bleeding, severe renal failure (creatinine clearance <10 mL/min) and/or severe hepatic
disease, uncontrolled hypertension.
The BOREALIS trial (21) was a multicentre, randomized, double-blind, double-
dummy, non-inferiority trial comparing idrabiotaparinux (or its placebo) and dose-adjusted
warfarin (or its placebo) for the prevention of thromboembolism in patients with AF. Inclu-
sion criteria were non-valvular, ECG- documented AF with an indication for long-term
VKA therapy based on the presence of previous ischemic stroke, transient ischemic attack,
or systematic thromboembolism and/or at least two of the following risk factors: hyperten-
sion requiring drug treatment; moderately or severely impaired left ventricular function
and/or heart failure; age ≥ 75 years; or diabetes mellitus. Exclusion criteria included:
severe renal failure (creatinine clearance < 30 mL/min), indication for VKA other than AF,
stroke or TIA within 5 days, uncontrolled hypertension, history of intracranial, intraocular,
spinal, overt gastrointestinal, retroperitoneal, or traumatic intra- articular bleeding or
life-threatening bleeding; active bleeding or high risk of bleeding.
References
1. Vitolo, M.; Proietti, M.; Harrison, S.; Lane, D.A.; Potpara, T.S.; Boriani, G.; Lip, G.Y.H. The Euro Heart Survey and EURObser-
vational Research Programme (EORP) in atrial fibrillation registries: Contribution to epidemiology, clinical management and
therapy of atrial fibrillation patients over the last 20 years. Intern. Emerg. Med. 2020, 15, 1183–1192. [CrossRef] [PubMed]
2. Proietti, M.; Lip, G.Y.H.; Laroche, C.; Fauchier, L.; Marin, F.; Nabauer, M.; Potpara, T.; Dan, G.A.; Kalarus, Z.; Tavazzi, L.; et al.
Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation:
An analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. EP Europace 2021, 23, 174–183.
[CrossRef] [PubMed]
3. Proietti, M.; Laroche, C.; Nieuwlaat, R.; Crijns, H.J.; Maggioni, A.P.; Lane, D.A.; Boriani, G.; Lip, G.Y. Increased burden of
comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between
EORP-AF pilot and EHS-AF registries. Eur. J. Intern. Med. 2018, 55, 28–34. [CrossRef]
4. Boriani, G.; Ruff, C.T.; Kuder, J.F.; Shi, M.; Lanz, H.J.; Antman, E.M.; Braunwald, E.; Giugliano, R.P. Edoxaban versus War-
farin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial.
Thromb. Haemost. 2021, 121, 140–149. [CrossRef] [PubMed]
5. Lee, S.R.; Choi, E.K.; Jung, J.H.; Park, S.H.; Han, K.D.; Oh, S.; Lip, G.Y. Body Mass Index and Clinical Outcomes in Asian Patients
with Atrial Fibrillation Receiving Oral Anticoagulation. Stroke 2021, 52, 521–530. [CrossRef]
6. Vitolo, M.; Lip, G.Y.H.; Shantsila, A. Why Is Atrial Fibrillation So Frequent in Hypertensive Patients? Am. J. Hypertens. 2020, 33,
1067–1070. [CrossRef]
7. Boriani, G.; Vitolo, M.; Diemberger, I.; Proietti, M.; Valenti, A.C.; Malavasi, V.L.; Lip, G.Y. Optimizing indices of AF susceptibility
and burden to evaluate AF severity, risk and outcomes. Cardiovasc. Res. 2021. [CrossRef]
8. Viticchi, G.; Falsetti, L.; Burattini, M.; Zaccone, V.; Buratti, L.; Bartolini, M.; Moroncini, G.; Silvestrini, M. Atrial Fibrillation on
Patients with Vascular Dementia: A Fundamental Target for Correct Management. Brain Sci. 2020, 10, 420. [CrossRef]
9. Falsetti, L.; Viticchi, G.; Buratti, L.; Grigioni, F.; Capucci, A.; Silvestrini, M. Interactions between Atrial Fibrillation, Cardiovascular
Risk Factors, and ApoE Genotype in Promoting Cognitive Decline in Patients with Alzheimer’s Disease: A Prospective Cohort
Study. J. Alzheimers Dis. 2018, 62, 713–725. [CrossRef]
10. Inohara, T.; Shrader, P.; Pieper, K.; Blanco, R.G.; Thomas, L.; Singer, D.E.; Freeman, J.V.; Allen, L.A.; Fonarow, G.C.; Gersh, B.; et al.
Association of of Atrial Fibrillation Clinical Phenotypes with Treatment Patterns and Outcomes: A Multicenter Registry Study.
JAMA Cardiol. 2018, 3, 54–63. [CrossRef]
11. Inohara, T.; Piccini, J.P.; Mahaffey, K.W.; Kimura, T.; Katsumata, Y.; Tanimoto, K.; Inagawa, K.; Ikemura, N.; Ueda, I.; Fukuda, K.;
et al. A Cluster Analysis of the Japanese Multicenter Outpatient Registry of Patients with Atrial Fibrillation. Am. J. Cardiol. 2019,
124, 871–878. [CrossRef]
12. Ahmad, T.; Pencina, M.J.; Schulte, P.J.; O’Brien, E.; Whellan, D.J.; Piña, I.L.; Kitzman, D.W.; Lee, K.L.; O’Connor, C.M.; Felker, G.M.
Clinical implications of chronic heart failure phenotypes defined by cluster analysis. J. Am. Coll. Cardiol. 2014, 64, 1765–1774.
[CrossRef] [PubMed]
13. Kwak, S.; Lee, Y.; Ko, T.; Yang, S.; Hwang, I.-C.; Park, J.-B.; Yoon, Y.E.; Kim, H.-L.; Kim, H.-K.; Kim, Y.-J.; et al. Unsuper-
vised Cluster Analysis of Patients with Aortic Stenosis Reveals Distinct Population with Different Phenotypes and Outcomes.
Circ. Cardiovasc. Imaging 2020, 13, e009707. [CrossRef] [PubMed]
Biomedicines 2021, 9, 843 11 of 11
14. Horiuchi, Y.; Tanimoto, S.; Latif, M.; Urayama, K.Y.; Aoki, J.; Yahagi, K.; Okuno, T.; Sato, Y.; Tanaka, T.; Koseki, K.; et al. Identifying
novel phenotypes of acute heart failure using cluster analysis of clinical variables. Int. J. Cardiol. 2018, 262, 57–63. [CrossRef]
[PubMed]
15. Parikh, K.S.; Rao, Y.; Ahmad, T.; Shen, K.; Felker, G.M.; Rajagopal, S. Novel approach to classifying patients with pulmonary
arterial hypertension using cluster analysis. Pulm. Circ. 2017, 7, 486–493. [CrossRef]
16. Ahmad, T.; Desai, N.; Wilson, F.; Schulte, P.; Dunning, A.; Jacoby, D.; Allen, L.; Fiuzat, M.; Rogers, J.; Felker, G.M.; et al. Clinical
Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside
Hemodynamic Profiles. PLoS ONE 2016, 11, e0145881. [CrossRef]
17. Shah, S.J.; Katz, D.; Selvaraj, S.; Burke, M.A.; Yancy, C.W.; Gheorghiade, M.; Bonow, R.O.; Huang, C.-C.; Deo, R.C. Phenomapping
for Novel Classification of Heart Failure with Preserved Ejection Fraction. Circulation 2015, 131, 269–279. [CrossRef]
18. Ernande, L.; Audureau, E.; Jellis, C.L.; Bergerot, C.; Henegar, C.; Sawaki, D.; Czibik, G.; Volpi, C.; Canoui-Poitrine, F.; Thibault, H.;
et al. Clinical Implications of Echocardiographic Phenotypes of Patients with Diabetes Mellitus. J. Am. Coll. Cardiol. 2017, 70,
1704–1716. [CrossRef]
19. Sevakula, R.K.; Au-Yeung, W.M.; Singh, J.P.; Heist, E.K.; Isselbacher, E.M.; Armoundas, A.A. State-of-the-Art Machine Learning
Techniques Aiming to Improve Patient Outcomes Pertaining to the Cardiovascular System. J. Am. Heart Assoc. 2020, 9, e013924.
[CrossRef]
20. Bousser, M.G.; Bouthier, J.; Büller, H.R.; Cohen, A.T.; Crijns, H.; Davidson, B.L.; Halperin, J.; Hankey, G.; Levy, S.; Pengo, V.; et al.
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation:
A randomised, open-label, non-inferiority trial. Lancet 2008, 371, 315–321.
21. Buller, H.R.; Halperin, J.; Hankey, G.J.; Pillion, G.; Prins, M.H.; Raskob, G.E. Comparison of idrabiotaparinux with vitamin K
antagonists for prevention of thromboembolism in patients with atrial fibrillation: The Borealis-Atrial Fibrillation Study. J. Thromb.
Haemost. JTH 2014, 12, 824–830. [CrossRef]
22. Malavasi, V.L.; Fantecchi, E.; Tordoni, V.; Melara, L.; Barbieri, A.; Vitolo, M.; Lip, G.Y.H.; Boriani, G. Atrial fibrillation pattern and
factors affecting the progression to permanent atrial fibrillation. Intern. Emerg. Med. 2020, 1–10. [CrossRef]
23. Vitolo, M.; Lip, G.Y.H. Understanding the global burden of atrial fibrillation and regional variations: We need improvement.
Cardiovasc. Res. 2021, 117, 1420–1422. [CrossRef] [PubMed]
24. Hindricks, G.; Potpara, T.; Dagres, N.; Arbelo, E.; Bax, J.J.; Blomström-Lundqvist, C.; Boriani, G.; Castella, M.; Dan, G.A.;
Dilaveris, P.E.; et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with
the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2021, 42, 373–498. [CrossRef]
25. Lip, G.Y.; Banerjee, A.; Boriani, G.; Chiang, C.E.; Fargo, R.; Freedman, B.; Lane, D.A.; Ruff, C.T.; Turakhia, M.; Werring, D.; et al.
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest 2018, 154, 1121–1201. [CrossRef]
[PubMed]
26. Boriani, G.; Vitolo, M.; Lane, D.A.; Potpara, T.S.; Lip, G.Y. Beyond the 2020 guidelines on atrial fibrillation of the European society
of cardiology. Eur. J. Intern. Med. 2021, 86, 1–11. [CrossRef]
27. Proietti, M.; Romiti, G.F.; Olshansky, B.; Lane, D.A.; Lip, G.Y.H. Comprehensive Management with the ABC (Atrial Fibrillation
Better Care) Pathway in Clinically Complex Patients with Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM
Trial. J. Am. Heart Assoc. 2020, 9, e014932. [CrossRef] [PubMed]
28. Guo, Y.; Lane, D.A.; Wang, L.; Zhang, H.; Wang, H.; Zhang, W.; Wen, J.; Xing, Y.; Wu, F.; Xia, Y.; et al. Mobile Health Technology
to Improve Care for Patients with Atrial Fibrillation. J. Am. Coll. Cardiol. 2020, 75, 1523–1534. [CrossRef]
29. Proietti, M.; Vitolo, M.; Lip, G.Y.H. Integrated care and outcomes in patients with atrial fibrillation and comorbidities. Eur. J. Clin.
Investig. 2021, 51, e13498. [CrossRef]
30. Malavasi, V.L.; Zoccali, C.; Brandi, M.C.; Micali, G.; Vitolo, M.; Imberti, J.F.; Mussi, C.; Schnabel, R.B.; Freedman, B.; Boriani, G.
Cognitive impairment in patients with atrial fibrillation: Implications for outcome in a cohort study. Int. J. Cardiol. 2021, 323,
83–89. [CrossRef]
